LIVN vs. ITGR, TMDX, CNMD, HAE, SLNO, INMD, BLFS, AXGN, OM, and MASI
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Integer (ITGR), TransMedics Group (TMDX), CONMED (CNMD), Haemonetics (HAE), Soleno Therapeutics (SLNO), InMode (INMD), BioLife Solutions (BLFS), AxoGen (AXGN), Outset Medical (OM), and Masimo (MASI). These companies are all part of the "medical" sector.
Integer (NYSE:ITGR) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
Integer has a net margin of 6.01% compared to Integer's net margin of -2.68%. Integer's return on equity of 13.59% beat LivaNova's return on equity.
Integer has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
99.3% of Integer shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.0% of Integer shares are held by company insiders. Comparatively, 0.2% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, LivaNova had 5 more articles in the media than Integer. MarketBeat recorded 13 mentions for LivaNova and 8 mentions for Integer. LivaNova's average media sentiment score of 0.98 beat Integer's score of 0.59 indicating that Integer is being referred to more favorably in the media.
Integer has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Integer currently has a consensus target price of $120.50, indicating a potential upside of 6.51%. LivaNova has a consensus target price of $66.20, indicating a potential upside of 6.07%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts clearly believe Integer is more favorable than LivaNova.
LivaNova received 5 more outperform votes than Integer when rated by MarketBeat users. Likewise, 68.78% of users gave LivaNova an outperform vote while only 63.39% of users gave Integer an outperform vote.
Summary
Integer beats LivaNova on 12 of the 18 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LivaNova Competitors List
Related Companies and Tools